Rosuvastatin reduces nonalcoholic fatty liver disease in patients with chronic hepatitis C treated with α-interferon and ribavirin: Rosuvastatin reduces NAFLD in HCV patients

BACKGROUND: Nonalcoholic fatty liver disease develops in patients with chronic hepatitis C. Interferon and ribavirin combination therapy is the standard treatment for chronic hepatitis C, but if present, NAFLD can reduce the virological response to anti-HCV therapies. OBJECTIVES: We determined wheth...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: Malaguarnera, Michele, Vacante, Marco, Russo, Cristina, Gargante, Maria Pia, Giordano, Maria, Bertino, Gaetano, Neri, Sergio, Malaguarnera, Mariano, Galvano, Fabio, Volti, Giovanni Li
Format: Artigo
Jezik:Inglês
Izdano: Kowsar 2011
Teme:
Original Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC3206670/
https://ncbi.nlm.nih.gov/pubmed/22087124
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki